Bibliographic Details
| Title: |
Impact of COVID-19 on patients undergoing scheduled procedures for chronic venous disease. |
| Authors: |
Moore, Ethan, Wohlauer, Max V, Dorosh, James, Kabeil, Mahmood, Malgor, Rafael D, O'Banion, Leigh A, Lopez-Pena, Gabriel, Gillette, Riley, Colborn, Kathryn, Cuff, Robert F, Lucero, Leah, Ali, Amna, Koleilat, Issam, Batarseh, Paola, Talathi, Sonia, Rivera, Aksim, Humphries, Misty D, Ly, Kevin, Harroun, Nikolai, Smith, Brigitte K |
| Source: |
Vascular; Apr2025, Vol. 33 Issue 2, p367-375, 9p |
| Abstract: |
Objective: The COVID-19 pandemic has drastically altered the medical landscape. Various strategies have been employed to preserve hospital beds, personal protective equipment, and other resources to accommodate the surges of COVID-19 positive patients, hospital overcapacities, and staffing shortages. This has had a dramatic effect on vascular surgical practice. The objective of this study is to analyze the impact of the COVID-19 pandemic on surgical delays and adverse outcomes for patients with chronic venous disease scheduled to undergo elective operations. Methods: The Vascular Surgery COVID-19 Collaborative (VASCC) was founded in March 2020 to evaluate the outcomes of patients with vascular disease whose operations were delayed. Modules were developed by vascular surgeon working groups and tested before implementation. A data analysis of outcomes of patients with chronic venous disease whose surgeries were postponed during the COVID-19 pandemic from March 2020 through February 2021 was performed for this study. Results: A total of 150 patients from 12 institutions in the United States were included in the study. Indications for venous intervention were: 85.3% varicose veins, 10.7% varicose veins with venous ulceration, and 4.0% lipodermatosclerosis. One hundred two surgeries had successfully been completed at the time of data entry. The average length of the delay was 91 days, with a median of 78 days. Delays for venous ulceration procedures ranged from 38 to 208 days. No patients required an emergent intervention due to their venous disease, and no patients experienced major adverse events following their delayed surgeries. Conclusions: Interventions may be safely delayed for patients with venous disease requiring elective surgical intervention during the COVID-19 pandemic. This finding supports the American College of Surgeons' recommendations for the management of elective vascular surgical procedures. Office-based labs may be safe locations for continued treatment when resources are limited. Although the interventions can be safely postponed, the negative impact on quality of life warrants further investigation. [ABSTRACT FROM AUTHOR] |
|
Copyright of Vascular is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
